Interview with Jing-Zhou Hou, MD who discusses results from a study comparing dose reductions and discontinuations between patients with chronic lymphocytic leukemia receiving ibrutinib in community and academic settings.
Interview with Jing-Zhou Hou, MD who discusses results from a study comparing dose reductions and discontinuations between patients with chronic lymphocytic leukemia receiving ibrutinib in community and academic settings.